REG - Venture Life Group - Trading Statement

Venture LifeAnnouncement

31/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220131:nRSe0581Aa&default-theme=true

RNS Number : 0581A  Venture Life Group PLC  31 January 2022

31(st) January 2022

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Full year trading and commercial update

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, is pleased to provide the
following trading and commercial update for the year ended 31 December 2021
("FY21").  The Company expects to publish its results for FY21 on 24 March
2022.

Highlights

·    Revenue of £32.6 million for the FY21(2020: £30.1 million), up 8%
on the prior year;

·    Revenue in the second half of the year was £18.7 million, an
increase of 35% over the revenues in the first half of the year (£13.9
million);

·    Momentum building in the business post acquisitions demonstrated by
Q4 revenue 59% above that in Q3; and

·    Adjusted EBITDA in line with market expectations;

·    Net debt of £3.2m pre-IFRS16 (£7.3m IFRS16) reflecting a phasing
effect on working capital as a result of higher receivables following strong
Q4 revenue.

The Board is pleased to report that the momentum seen in the second half of
the 2021 has continued into 2022 and that the order book for the Group is
significantly ahead of the same time last year, underpinning our confidence in
the year ahead.

As previously announced earlier this month the Group appointed a new partner,
Samarkand Global plc, for its oral care products in China and shipments have
already commenced to this partner.

We are also pleased to report that a leading UK health and beauty retailer has
confirmed they will launch our in-house developed product for rosacea in the
UK and Ireland later in H1 2022 with the product being marketed under their
own brand.  This marks the first product launch under this retailer's own
brand and paves the way for future collaboration.  Furthermore, another key
UK health and beauty retailer will launch our Wart & Verruca Pen and
Women's Intimate Gel in H2 2022 under their own brand; finally, other new
agreements have been recently completed for other products in other
territories.

Following the successful integration of BBI Healthcare and Helsinn
acquisitions, one of these new agreements has been signed for Pomi-T in
Germany, which marks the start of the expansion plan of this product into key
markets around the world, in another of the 5 major EU markets.

 

Jerry Randall, CEO of Venture Life, commented, '2021 was a difficult year for
the Group given the significant headwinds experienced, and I am pleased with
the revenues delivered.  As with many businesses supply chain and logistics
continue to be an issue but we are managing these challenges to meet the needs
of our suppliers, our customers and ourselves. The partnership with our new
partner for China has started well, and we look forward to a long and
successful relationship with them. The acquisitions we made in 2021 are now
fully integrated and have performed extremely well, contributing significantly
to our strong growth in revenue and profitability in the second half. We have
started 2022 with an order book significantly ahead of the same time last
year, giving us a good level of confidence for the year ahead. I would like to
acknowledge the efforts of the whole team at Venture Life in delivering the
second half revenues in extremely challenging supply chain circumstances, and
I give my thanks to each and every one of them'.

 

 

For further information, please contact:

 

 Venture Life Group PLC                              +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cenkos Securities plc (Nomad and Joint Broker)      +44 (0) 20 7397 8900
 Michael Johnson/Russell Kerr (Sales)

 Stephen Keys/Camilla Hume (Corporate Finance)

 Singer Capital markets (Joint Broker)               +44 (0) 20 7496 3000
 Jonathan Dighe (Sales)

 Shaun Dobson/Alaina Wong (Corporate Finance)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Active range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, products for fungal infections and proctology, and
dermo-cosmetics for addressing the signs of ageing. Its products are sold in
over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTQBLFXLFLFBBF